
<DOC>
<DOCNO>WT02-B15-67</DOCNO>
<DOCOLDNO>IA027-000293-B027-236</DOCOLDNO>
<DOCHDR>
http://www.bernaproducts.com:80/10_medhmpg.html 206.136.243.10 19970117021711 text/html 1645
HTTP/1.0 200 OK
Date: Fri, 17 Jan 1997 05:08:12 GMT
Server: Apache/1.1.0
Content-type: text/html
Content-length: 1474
Last-modified: Tue, 01 Oct 1996 06:58:11 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//SQ//DTD HTML 2.0 HoTMetaL + extensions//EN">
<HTML>
<HEAD>
   
<TITLE>10_medhmpg</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff"><CENTER><A HREF="image10.map"><IMG
SRC="image10.gif" ISMAP="ismap" WIDTH="468" HEIGHT="357" BORDER="0" ALIGN="middle"></A></CENTER>
<P>Photograph depicts the colony morphology of virulent<I> S. typhi</I> Ty2
(large yellow colonies) and the attenuated Ty21a vaccine strain (smaller darker
colonies) derived from Ty2.  The change in color and morphology of Ty21a is the
result of a genetic mutation linked to the attenuation of the strain.</P>
<P>The ability of S. typhi to cause disease and to induce a protective immune
response is dependent upon the bacteria possessing a complete
lipopolysaccharide. The S. typhi Ty21a vaccine strain, by virtue of a reduction
in enzymes essential for lipopolysaccharide biosynthesis, is restricted in its
ability to produce complete lipopolysaccharide. However, a sufficient quantity
of complete lipopolysaccharide is synthesized to evoke a protective immune
response. Despite low levels of lipopolysaccharide synthesis, the cells lyse
before regaining a virulent phenotype due to the intracellular build-up of
intermediates during lipopolysaccharide synthesis.  (<A
HREF="11_oralroute.html#11_oralroute.html">For
more information see Oral Route</A>)</P>

<P ALIGN=CENTER>Development and Design by:
<A HREF="mailto:sgeraci@colossalmultimedia.com">Colossal Multimedia</A></P>
</BODY>
</HTML>
</DOC>